Tuyen Ong

Tuyen Ong joined Flagship Pioneering in 2020 where he serves as both a CEO-Partner and Chief Executive Officer of Ring Therapeutics.

Tuyen is an accomplished biotechnology and pharmaceutical executive with a wealth of experience in company growth, R&D and gene therapy. He has a passion for driving progress in life sciences and bringing innovation to patients, having led the development of breakthrough treatments for retinopathies and rare diseases.

He was most recently Senior Vice President, Head of the Ophthalmology Franchise at Biogen and was Chief Development Officer at Nightstar Therapeutics until it was acquired by Biogen in 2019. While there, he was involved with the company’s NASDAQ IPO, corporate and gene therapy strategy, as well as investor and M&A activities.

Prior to this, Tuyen served as Chief Medical Officer at PTC Therapeutics and was responsible for progressing its pipeline of therapies for rare and orphan diseases. He served as joint steering committee member overseeing the development of Risdiplam for the treatment of SMA. He also held leadership roles at Bausch and Lomb, where he played a lead role in the company’s filing of new drug and device applications, and at Pfizer, where he served as global clinical lead across several therapeutic disease areas.

Tuyen was awarded his M.D. from University College London and his M.B.A. from New York University Stern School of Business. He is a member of the Royal College of Ophthalmologists and a Churchill Fellow.